Gilead says COVID drug remdesivir shows antiviral activity against Omicron, other variants – Reuters

The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake
Feb 11 (Reuters) – Gilead Sciences Inc’s (GILD.O) drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.
The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.
Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease. read more
Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.
"Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant," said Tomas Cihlar, senior vice president of virology research at Gilead.
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved


Leave a Reply

Your email address will not be published.